Shen Song, MD
Nephrology · Mount Prospect
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 16 years
- University of Texas Medical School at Houston, 2010
Offices
1 location · Nephrology Associates of Northern Illinois Ltd · 117 clinicians in this group
Hospitals listed: 142655 · 142723 · 142774 · Advocate Lutheran General Hospital · Northwest Community Hospital 1. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Song’s office at (847) 439-8780 to ask if they take your plan before you enroll.
California Medical Board record
Licence A150126 · Delinquent
Licence status: Delinquent · since 2017 · expires 2022-07-31 · University of Texas Medical School at Houston.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Illinois 036156218Licensed Physician And Surgeon · since 2021 · expires 2029-07-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Advocate Lutheran General HospitalPark Ridge, ILAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Advocate Health, which runs 58 hospitals in 6 statesPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.5 (10.8 to 16.6) · 325 cases, Jan 2024 – Dec 2024Better than the national rate — Pressure ulcer rate: 0.2 (0 to 0.6) · 12,230 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.422, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.367, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.498, Oct 2024 – Sep 2025
- Northwest Community Hospital 1Arlington Heights, ILAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of NorthShore � Edward-Elmhurst Health, which runs 8 hospitalsPatients rate it 2 of 5 · 64% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.74 (0.51 to 0.97), Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 4.3 (0.05 to 8.56) · 1,650 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.353, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Advocate Lutheran General Hospital
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.8 to 16.6) · 325 cases | Worse | Jan 2024 – Dec 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.6) · 12,230 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.422 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.367 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.498 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.58 (0 to 1.39) · 2,497 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.63 to 1.07) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 144.39 (110.97 to 177.81) · 194 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 75 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.7 · 183 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.5 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 1,210 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.4 · 1,211 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.8 · 762 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 6,370 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.3 (0.12 to 0.47) · 13,662 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 13,907 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.05 (1.43 to 4.66) · 3,062 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.91 (0.55 to 3.27) · 1,359 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.08 to 3.64) · 2,827 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.82 (3.33 to 12.31) · 1,321 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.48 (3.61 to 9.35) · 1,294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.51 (0.09 to 2.92) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 93 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.073 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.782 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.956 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 290 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.3 · 1,571 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -3.7 · 232 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 9 · 1,358 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.7 · 1,251 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.3 · 1,523 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.4 (3.1 to 6.1) · 325 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 104 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.4 · 103 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 223 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.3 (10.7 to 16.3) · 3,296 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 957 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,055 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Northwest Community Hospital 1
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 8 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.74 (0.51 to 0.97) | Better | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.3 (0.05 to 8.56) · 1,650 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.353 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.98 (0.13 to 1.82) · 2,729 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 161.59 (115.02 to 208.17) · 136 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 113 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 5.3 · 254 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 279 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 837 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.4 · 1,280 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.7 · 547 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 5,886 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0.01 to 0.35) · 15,605 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.13 to 0.48) · 15,546 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.12 (1.49 to 4.75) · 3,427 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.48 (0.18 to 2.79) · 1,663 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.34 (1.07 to 3.62) · 3,233 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.44 (1.9 to 6.97) · 1,640 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.41 (0.04 to 2.77) · 788 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.4 (0 to 0.9) · 13,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.6 · 455 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.414 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.507 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.251 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.4 · 264 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 909 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.6 · 268 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -10.3 · 944 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -6.4 · 1,317 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.2 · 1,368 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.2 to 7.7) · 88 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.6 to 13.8) · 88 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 436 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12 · 126 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 295 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.6 to 14.4) · 4,975 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 926 cases | No different | Jan 2024 – Dec 2024 |
What patients said (417 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 64% |
| Nurses "always" treated them with courtesy and respect | 79% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 79% |
Original Medicare doctor bills
$202,633
Medicare paid this office $202,633 for 793 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 493 | $72,695 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 164 | $32,484 | $96 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 14 | $26,982 | $275 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 215 | $24,626 | $106 |
| Return visit (30+ min) | 115 | $17,385 | $74 |
See all 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 493 | $72,695 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 164 | $32,484 | $96 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 14 | $26,982 | $275 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 215 | $24,626 | $106 |
| Return visit (30+ min) | 115 | $17,385 | $74 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $8,812 | $140 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 18 | $3,908 | $51 |
| New patient visit (45+ min) | 29 | $3,792 | $131 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 88 | $2,234 | $13 |
| Hemodialysis procedure with physician evaluation | 11 | $568 | $52 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 12 | $509 | $39 |
Who their Medicare patients are
793 Original Medicare patients in 2024. Average age 77 · Under 65 10% · 85 and older 27% · Women 49% · Also on Medicaid 28% · Health risk score 4.09. Above the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Heart failure 65% · Diabetes 62% · Coronary heart disease 60% · Atrial fibrillation 47% · Depression 38% · COPD 32% · Stroke 27% · Dementia 26% · Cancer 22%.
The office billed $548,836, Medicare allowed $263,413 and paid $202,633; for 2,460 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 793 | 2,460 | 77 | 4.09 | $548,836 | $202,633 |
| 2023 | 702 | 2,054 | 77 | 4.45 | $442,734 | $184,685 |
| 2022 | 883 | 3,178 | 78 | 3.65 | $665,858 | $273,426 |
| 2021 | 408 | 1,140 | 76 | 3.19 | $268,325 | $104,866 |
| 2020 | 25 | 34 | 69 | 1.28 | $21,955 | $4,442 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 441 | $66,832 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 139 | $29,531 | $99 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 16 | $24,677 | $280 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 183 | $20,838 | $109 |
| Return visit (30+ min) | 83 | $12,189 | $86 |
| Home dialysis services per month (20 years or older) | 18 | $7,868 | $238 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $5,472 | $144 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 16 | $5,079 | $52 |
| Hemodialysis procedure with physician evaluation | 42 | $4,094 | $59 |
| New patient visit (45+ min) | 22 | $2,645 | $120 |
| Short return visit (20+ min) | 13 | $1,052 | $70 |
2022: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 639 | $109,780 | $60 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 23 | $44,715 | $292 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 316 | $39,852 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 133 | $26,773 | $86 |
| Return visit (30+ min) | 75 | $12,333 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $7,341 | $167 |
| New patient visit (45+ min) | 55 | $6,822 | $124 |
| Hemodialysis procedure with physician evaluation | 54 | $4,938 | $61 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 26 | $4,848 | $53 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 19 | $767 | $40 |
2021: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 257 | $41,765 | $61 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 19 | $18,069 | $306 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 120 | $14,629 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $7,363 | $88 |
| New patient visit (45+ min) | 40 | $5,794 | $145 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,241 | $162 |
| Return visit (30+ min) | 20 | $2,646 | $110 |
| Return visit (30+ min) | 22 | $2,327 | $80 |
| Hemodialysis procedure with physician evaluation | 20 | $1,486 | $62 |
2020: 1 service
| New patient visit (60+ min) | 21 | $3,265 | $155 |
Medicaid work
$11,713 in 2024
Medicaid paid $11,713 for 420 billed services this clinician did in 2024, up to 30 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 420 | $11,713 |
| 2024 | 420 | 1 | 30 | $11,713 |
| 2023 | 475 | 2 | 35 | $10,937 |
| 2022 | 939 | 3 | 44 | $20,660 |
| 2021 | 334 | 2 | 40 | $7,282 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 448 | $9,799 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 27 | $1,139 |
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 830 | $17,063 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 74 | $2,074 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 35 | $1,523 |
2021
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 306 | $6,177 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 28 | $1,105 |
Drugs they prescribed that Part D paid
$172,457
Pharmacies billed $172,457 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 583) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
439 generic and 144 brand-name prescriptions · $172,457 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 86 | $102,082 | $1,187 |
| Veltassa | 12 | $29,992 | $2,499 |
| Farxiga | 11 | $13,093 | $1,190 |
| Sevelamer Carbonate | 19 | $2,367 | $125 |
| Bumetanide | 19 | $954 | $50 |
See all 16 drugs
| Jardiance | 86 | $102,082 | $1,187 |
| Veltassa | 12 | $29,992 | $2,499 |
| Farxiga | 11 | $13,093 | $1,190 |
| Sevelamer Carbonate | 19 | $2,367 | $125 |
| Bumetanide | 19 | $954 | $50 |
| Calcitriol | 51 | $862 | $17 |
| Hydralazine | 29 | $768 | $26 |
| Amlodipine Besylate | 56 | $688 | $12 |
| Nifedipine Er | 22 | $326 | $15 |
| Furosemide | 30 | $312 | $10 |
| Spironolactone | 18 | $250 | $14 |
| Losartan | 24 | $214 | $9 |
| Carvedilol | 17 | $143 | $8 |
| Allopurinol | 18 | $133 | $7 |
| Lisinopril | 33 | $122 | $4 |
| Metoprolol | 11 | $78 | $7 |
Year by year
| 2024 | 583 | 120 | 0% (0) | 25% | $172,457 |
| 2023 | 307 | 91 | 0% (0) | 16% | $62,612 |
| 2022 | 320 | 75 | 0% (0) | 10% | $28,429 |
| 2021 | 91 | 32 | 0% (0) | None | $10,068 |
| 2020 | 11 | None | 0% (0) | None | $190 |
| 2017 | 32 | None | 0% (0) | 50% | $2,879 |
| 2016 | 68 | None | 0% (0) | None | $1,638 |
| 2015 | 208 | 26 | None | None | $9,217 |
| 2014 | 32 | None | None | None | $2,800 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Jardiance | 30 | $38,230 | $1,274 |
| Farxiga | 14 | $13,033 | $931 |
| Amlodipine Besylate | 32 | $698 | $22 |
| Calcitriol | 22 | $522 | $24 |
| Losartan | 24 | $512 | $21 |
| Spironolactone | 22 | $449 | $20 |
| Furosemide | 29 | $404 | $14 |
| Lisinopril | 26 | $340 | $13 |
| Chlorthalidone | 11 | $253 | $23 |
| Allopurinol | 14 | $144 | $10 |
| Carvedilol | 13 | $91 | $7 |
2022: 6 drugs
| Amlodipine Besylate | 56 | $753 | $13 |
| Lisinopril | 32 | $473 | $15 |
| Furosemide | 39 | $412 | $11 |
| Losartan | 34 | $333 | $10 |
| Spironolactone | 12 | $318 | $27 |
| Hydrochlorothiazide | 15 | $224 | $15 |
2021: 3 drugs
| Chlorthalidone | 15 | $224 | $15 |
| Amlodipine Besylate | 18 | $200 | $11 |
| Lisinopril | 12 | $81 | $7 |
2016: 1 drug
| Clopidogrel | 11 | $39 | $4 |
2015: 9 drugs
| Potassium Chloride | 16 | $222 | $14 |
| Metoprolol | 14 | $195 | $14 |
| Atorvastatin | 13 | $132 | $10 |
| Pramipexole Dihydrochloride | 12 | $91 | $8 |
| Clopidogrel | 14 | $85 | $6 |
| Gabapentin | 14 | $60 | $4 |
| Carvedilol | 14 | $59 | $4 |
| Lisinopril | 12 | $34 | $3 |
| Furosemide | 13 | $29 | $2 |
Money from drug and device companies
$816 in 2025
| 2025 | 16 | 32 | None | $816 |
| 2024 | 16 | 38 | None | $865 |
| 2023 | 3 | 3 | None | $75 |
| 2022 | 4 | 8 | None | $234 |
| 2021 | 4 | 5 | None | $183 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Fabhalta | $189 | 7 payments
|
| Calliditas Therapeutics US | Tarpeyo | $101 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $95 | 3 payments
|
| Amgen | Krystexxa | $84 | 3 payments
|
| Otsuka America Pharmaceutical | Jynarque | $49 | 2 payments
|
| Otsuka Pharmaceutical Development & Commercialization | None | $48 | 2 payments
|
See all 32 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-10 | Farxiga | $32 |
| Novartis Pharmaceuticals | Meals · 2025-12-03 | Fabhalta | $23 |
| Calliditas Therapeutics US | Meals · 2025-11-24 | Tarpeyo | $36 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-19 | Jardiance | $15 |
| Amgen | Meals · 2025-11-17 | Krystexxa | $31 |
| GlaxoSmithKline | Meals · 2025-11-03 | Arexvy | $21 |
| Amgen | Meals · 2025-10-29 | Tavneos | $25 |
| Otsuka America Pharmaceutical | Meals · 2025-10-01 | Jynarque | $25 |
| Novartis Pharmaceuticals | Meals · 2025-09-29 | Fabhalta | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-24 | Farxiga | $31 |
| Novartis Pharmaceuticals | Meals · 2025-09-17 | Fabhalta | $30 |
| Novartis Pharmaceuticals | Meals · 2025-08-13 | Fabhalta | $22 |
| Calliditas Therapeutics US | Meals · 2025-08-06 | Tarpeyo | $24 |
| Amgen | Meals · 2025-08-04 | Krystexxa | $28 |
| Scpharmaceuticals | Meals · 2025-07-30 | Furoscix | $28 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-07-23 | None | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-16 | Farxiga | $32 |
| Otsuka America Pharmaceutical | Meals · 2025-07-09 | Jynarque | $24 |
| Lilly USA | Meals · 2025-07-03 | Jardiance | $21 |
| Novartis Pharmaceuticals | Meals · 2025-07-02 | None | $31 |
| Calliditas Therapeutics US | Meals · 2025-06-11 | Tarpeyo | $14 |
| Akebia Therapeutics | Meals · 2025-06-11 | Vafseo | $30 |
| Novo Nordisk | Meals · 2025-03-12 | Ozempic | $23 |
| Novartis Pharmaceuticals | Meals · 2025-03-05 | None | $25 |
| Calliditas Therapeutics US | Meals · 2025-02-26 | Tarpeyo | $27 |
| Ardelyx | Meals · 2025-02-19 | Ibsrela | $20 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-07 | Jardiance | $20 |
| Alexion Pharmaceuticals | Meals · 2025-02-05 | Ultomiris | $25 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-05 | Kerendia | $25 |
| Novartis Pharmaceuticals | Meals · 2025-01-29 | None | $30 |
| Fresenius USA Marketing | Meals · 2025-01-15 | Velphoro | $23 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-01-07 | None | $22 |
See earlier years (2024, 2023, 2022, 2021)
2024: $865
| AstraZeneca Pharmaceuticals LP | Farxiga | $133 | 7 payments
|
| Amgen | Tavneos | $125 | 5 payments
|
| Novartis Pharmaceuticals | None | $84 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $64 | 3 payments
|
| Aurinia Pharma U.S. | Lupkynis | $61 | 2 payments
|
| Novo Nordisk | Rivfloza | $52 | 3 payments
|
| Mallinckrodt Hospital Products | Acthar | $51 | 2 payments
|
| Fresenius USA Marketing | Velphoro | $49 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $46 | 2 payments
|
| Calliditas Therapeutics US | Tarpeyo | $40 | 2 payments
|
| Lilly USA | Jardiance | $35 | 2 payments
|
| Travere Therapeutics | None | $28 | 1 payment
|
| Vifor Pharma | Veltassa | $25 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $25 | 1 payment
|
| Otsuka Pharmaceutical Development & Commercialization | None | $24 | 1 payment
|
| Ardelyx | Ibsrela | $23 | 1 payment
|
2023: $75
| Bayer Healthcare Pharmaceuticals | Kerendia | $31 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $28 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $16 | 1 payment
|
2022: $234
| Amgen | Tavneos | $86 | 2 payments
|
| Vifor Pharma | Veltassa | $80 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $50 | 2 payments
|
| Calliditas Therapeutics US | Tarpeyo | $18 | 1 payment
|
2021: $183
| Aurinia Pharma U.S. | Lupkynis | $105 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $44 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $18 | 1 payment
|
| Vifor Pharma | Veltassa | $17 | 1 payment
|
Professional record
- NPI
- 1518386911
- Licence
- CA A150126, IL 036.156218California A150126: Delinquent · expires 2022-07-31Illinois 036156218: Active
- Trained
- University of Texas Medical School at Houston, 2010 · 16 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X)
- Mailing address
- 120 W 22nd St Ste 200, Oak Brook, IL, 60523
- NPI first listed
- 2014-04-14
- NPI last updated
- 2022-05-31
- NPI record certified
- 2022-05-31
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1875 W Dempster St Ste 605, Park Ridge, IL, 60068 · 5999 New Wilke Rd Bldg 2, Rolling Meadows, IL, 60008 · 300 Pasteur Dr, Stanford, CA, 94305
This office lists an electronic records connection.